MX370174B - Peptido dendrimeros que comprenden peptidos de union a fibrinogenos. - Google Patents
Peptido dendrimeros que comprenden peptidos de union a fibrinogenos.Info
- Publication number
- MX370174B MX370174B MX2016008876A MX2016008876A MX370174B MX 370174 B MX370174 B MX 370174B MX 2016008876 A MX2016008876 A MX 2016008876A MX 2016008876 A MX2016008876 A MX 2016008876A MX 370174 B MX370174 B MX 370174B
- Authority
- MX
- Mexico
- Prior art keywords
- amino acid
- functional amino
- acid residues
- fibrinogen
- separately
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
- A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/641—Branched, dendritic or hypercomb peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0052—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
La presente invención se refiere a un péptido-dendríemro caracterizado porque comprende un núcleo ramificado, y una pluralidad de péptidos de unión a fibrinógeno unidos covalentemente por separado al núcleo ramificado, en donde el núcleo ramificado comprende: de dos a diez residuos de aminoácido multifuncionales, en donde cada péptido de unión a fibrinógeno es unido covalentemente por separado a un residuo de aminoácidos multifuncionales del núcleo ramificado; una pluralidad de residuos de aminoácido multifuncionales, en donde uno o más péptidos de unión a fibrinógeno están unidos covalentemente por separado a cada uno de al menos dos residuos de aminoácido multifuncionales adyacentes del núcleo ramificado; una pluralidad de residuos de aminoácido multifuncionales, en donde dos o más péptidos de unión a fibrinógeno están unidos covalentemente por separado a al menos uno de los residuos de aminoácidos multifuncionales del núcleo ramificado; una pluralidad de residuos de aminoácido multifuncionales, en donde dos o más residuos de aminoácido multifuncionales están vinculados covalentemente a través de una cadena lateral de un residuo de aminoácido multifuncional adyacente; o un único residuo de aminoácido multifuncional, y un péptido de unión a fibrinógeno está unidos covalentemente por separado a cada grupo funcional del residuo de aminoácido multifuncional, en donde los residuos de aminoácido multifuncionales comprende residuos de aminoácido tri-o tetra funcionales, o residuo de aminoácido tri- o tetra funcional, o el único residuo de aminoácido multifuncional es un residuo de aminoácido tri- o tetra- funcional.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1400292.7A GB201400292D0 (en) | 2014-01-08 | 2014-01-08 | Peptide dendrimers and agents |
| PCT/GB2015/050024 WO2015104544A1 (en) | 2014-01-08 | 2015-01-08 | Peptide dendrimers comprising fibrinogen-binding peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016008876A MX2016008876A (es) | 2016-12-02 |
| MX370174B true MX370174B (es) | 2019-12-04 |
Family
ID=50191056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016008876A MX370174B (es) | 2014-01-08 | 2015-01-08 | Peptido dendrimeros que comprenden peptidos de union a fibrinogenos. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10994047B2 (es) |
| EP (1) | EP3092011B1 (es) |
| JP (1) | JP6717747B2 (es) |
| KR (1) | KR102410065B1 (es) |
| CN (1) | CN105916524B (es) |
| AU (1) | AU2015205438B2 (es) |
| BR (1) | BR112016015701A2 (es) |
| CA (1) | CA2935888A1 (es) |
| ES (1) | ES2848031T3 (es) |
| GB (1) | GB201400292D0 (es) |
| HR (1) | HRP20210184T1 (es) |
| IL (1) | IL246611A0 (es) |
| MX (1) | MX370174B (es) |
| PH (1) | PH12016501308A1 (es) |
| RU (1) | RU2719562C2 (es) |
| SG (1) | SG11201605581UA (es) |
| WO (1) | WO2015104544A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201508024D0 (en) * | 2015-05-11 | 2015-06-24 | Haemostatix Ltd | Haemostatic compositions |
| WO2018065789A1 (en) | 2016-10-06 | 2018-04-12 | Matoke Holdings Limited | Antimicrobial compositions |
| BR112019006932A2 (pt) | 2016-10-06 | 2019-07-02 | Matoke Holdings Ltd | composições antimicrobianas |
| CN107625968B (zh) * | 2017-09-20 | 2020-09-29 | 四川大学 | 一种肿瘤特异性组织-细胞双渗透纳米粒、制备方法及其应用 |
| JP7358353B2 (ja) | 2018-01-04 | 2023-10-10 | アムリット・リサーチ・リミテッド | ベツリン含有白樺樹皮抽出物およびその製剤 |
| US10621579B2 (en) | 2018-09-06 | 2020-04-14 | Intercontinental Exchange Holdings, Inc. | Multi-signature verification network |
| CN110448719B (zh) * | 2019-06-28 | 2020-05-22 | 浙江大学 | 一种促进凝血的丝素-多肽电纺膜及其制备方法 |
| CN115397454A (zh) * | 2020-03-31 | 2022-11-25 | 立美基股份有限公司 | 通过辐照对自组装肽进行灭菌 |
| US11666682B2 (en) * | 2020-08-31 | 2023-06-06 | Ethicon, Inc. | Method of stopping CSF leaks and apparatus therefor |
| CN112206307B (zh) * | 2020-09-15 | 2023-12-05 | 广州领晟医疗科技有限公司 | 一种可注射的温敏型水凝胶及其制备方法与应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996017633A1 (en) | 1994-12-07 | 1996-06-13 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
| GB9524630D0 (en) * | 1994-12-24 | 1996-01-31 | Zeneca Ltd | Chemical compounds |
| GB9613112D0 (en) | 1996-06-21 | 1996-08-28 | Zeneca Ltd | Chemical compounds |
| CN1222918A (zh) * | 1996-06-21 | 1999-07-14 | 曾尼卡有限公司 | 细胞粘连抑制剂 |
| US20090087878A9 (en) * | 1999-05-06 | 2009-04-02 | La Rosa Thomas J | Nucleic acid molecules associated with plants |
| FR2813080B1 (fr) * | 2000-08-17 | 2002-11-29 | Stago Diagnostica | Peptides anti-heparine |
| US6506365B1 (en) | 2000-09-25 | 2003-01-14 | Baxter Aktiengesellschaft | Fibrin/fibrinogen binding conjugate |
| WO2004045494A2 (en) | 2002-11-20 | 2004-06-03 | Bar-Ilan University | Biological glue based on thrombin-conjugated nanoparticles |
| CA2530032C (en) | 2003-06-16 | 2015-11-24 | Loma Linda University Medical Center | Deployable multifunctional hemostatic agent |
| JP2008507362A (ja) | 2004-07-22 | 2008-03-13 | ヘモ ナノサイエンス リミテッド ライアビリティ カンパニー | 過剰な出血を処置するための組成物および方法 |
| GB0516091D0 (en) * | 2005-08-04 | 2005-09-14 | Haemostatix Ltd | Therapeutic agent |
| GB0623607D0 (en) * | 2006-11-27 | 2007-01-03 | Haemostatix Ltd | Tissue adhesive |
| US20100021527A1 (en) | 2008-07-25 | 2010-01-28 | Chunlin Yang | Collagen-related peptides and uses thereof and hemostatic foam substrates |
| US20130310853A1 (en) | 2009-01-09 | 2013-11-21 | Abbott Cardiovascular Systems Inc. | Method and apparatus for percutaneous treatment of a blood vessel |
| US8513380B2 (en) * | 2009-07-09 | 2013-08-20 | Georgia Tech Research Corporation | Peptides for binding fibrinogen and fibrin |
| GB201101740D0 (en) * | 2011-02-01 | 2011-03-16 | Haemostatix Ltd | Therapeutic agents with improved fibrinogen binding |
| EP2582051A1 (en) | 2011-10-13 | 2013-04-17 | ST-Ericsson SA | Multi-level sigma-delta ADC with reduced quantization levels |
| GB201201751D0 (en) * | 2012-02-01 | 2012-03-14 | Haemostatix Ltd | Haemostatic wound dressing |
-
2014
- 2014-01-08 GB GBGB1400292.7A patent/GB201400292D0/en not_active Ceased
-
2015
- 2015-01-08 WO PCT/GB2015/050024 patent/WO2015104544A1/en active Application Filing
- 2015-01-08 JP JP2016544565A patent/JP6717747B2/ja active Active
- 2015-01-08 ES ES15701237T patent/ES2848031T3/es active Active
- 2015-01-08 BR BR112016015701A patent/BR112016015701A2/pt not_active Application Discontinuation
- 2015-01-08 MX MX2016008876A patent/MX370174B/es active IP Right Grant
- 2015-01-08 KR KR1020167019889A patent/KR102410065B1/ko active IP Right Grant
- 2015-01-08 EP EP15701237.8A patent/EP3092011B1/en active Active
- 2015-01-08 AU AU2015205438A patent/AU2015205438B2/en active Active
- 2015-01-08 SG SG11201605581UA patent/SG11201605581UA/en unknown
- 2015-01-08 CA CA2935888A patent/CA2935888A1/en active Pending
- 2015-01-08 CN CN201580004811.1A patent/CN105916524B/zh active Active
- 2015-01-08 US US15/110,630 patent/US10994047B2/en active Active
- 2015-01-08 RU RU2016130448A patent/RU2719562C2/ru active
-
2016
- 2016-06-30 PH PH12016501308A patent/PH12016501308A1/en unknown
- 2016-07-05 IL IL246611A patent/IL246611A0/en unknown
-
2021
- 2021-02-02 HR HRP20210184TT patent/HRP20210184T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20210184T1 (hr) | 2021-04-30 |
| EP3092011B1 (en) | 2020-11-18 |
| US20160324977A1 (en) | 2016-11-10 |
| GB201400292D0 (en) | 2014-02-26 |
| JP2017505298A (ja) | 2017-02-16 |
| US10994047B2 (en) | 2021-05-04 |
| AU2015205438B2 (en) | 2018-11-08 |
| CN105916524B (zh) | 2021-07-20 |
| ES2848031T3 (es) | 2021-08-05 |
| RU2016130448A3 (es) | 2018-06-25 |
| WO2015104544A1 (en) | 2015-07-16 |
| CN105916524A (zh) | 2016-08-31 |
| KR102410065B1 (ko) | 2022-06-16 |
| AU2015205438A1 (en) | 2016-08-11 |
| JP6717747B2 (ja) | 2020-07-01 |
| PH12016501308A1 (en) | 2016-08-15 |
| KR20160105820A (ko) | 2016-09-07 |
| BR112016015701A2 (pt) | 2017-10-03 |
| SG11201605581UA (en) | 2016-08-30 |
| IL246611A0 (en) | 2016-08-31 |
| RU2719562C2 (ru) | 2020-04-21 |
| RU2016130448A (ru) | 2018-02-16 |
| CA2935888A1 (en) | 2015-07-16 |
| EP3092011A1 (en) | 2016-11-16 |
| MX2016008876A (es) | 2016-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501308A1 (en) | Peptide dendrimers comprising fibrinogen-binding peptides | |
| CY1121560T1 (el) | Ανοσογονικη συνθεση | |
| ES2691070T3 (es) | Péptidos antiinflamatorios y composición que comprende los mismos | |
| ES2693321T3 (es) | Péptidos antiinflamatorios y composición que comprende los mismos | |
| UA118167C2 (uk) | Пептид та його застосування | |
| DOP2013000310A (es) | Receptores co-agonistas glucagon/glp-1 | |
| MX2017002969A (es) | Composiciones detergentes que contienen un surfactante ramificado. | |
| CR20130667A (es) | Composiciones que contienen, mètodos que involucran, y usos derivados de dolastatina unidos a aminoàcidos no naturales | |
| AU2015208932A8 (en) | (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase I inhibitors | |
| BR112017004640A2 (pt) | produtos semiacabados compósitos, partes moldadas produzidas a partir dos mesmos, e partes moldadas diretamente produzidas com base em (met)acrilatos funcionalizados por hidróxi e uretdionas que são reticuladas de uma maneira termorrígida | |
| MX2013015168A (es) | Co-agonista del receptor de glucagon/glp-1. | |
| WO2014058232A3 (ko) | 스파이로형 유기 재료 및 이를 이용한 유기 전기발광 소자 | |
| CR20170197A (es) | Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidópteros | |
| MX2013011548A (es) | Formulaciones de agente de curtido particulado sólido. | |
| EA201491959A1 (ru) | Агонистические пептиды для par4 | |
| GB201215159D0 (en) | Composition | |
| CU20190078A7 (es) | Péptidos útiles en el tratamiento de diabetes | |
| CL2017003144A1 (es) | Péptidos lipidados resistentes a proteasas | |
| EA201300733A1 (ru) | Рекомбинантные микобактерии в качестве вакцины | |
| IN2014DN09367A (es) | ||
| MX2017005906A (es) | Composicion de concentrados para la extension de cadenas polimericas. | |
| UY34312A (es) | Compuesto de benzotiazolona | |
| NZ717192A (en) | Anti-inflammatory tripeptides | |
| MX2015012905A (es) | Formulaciones de factor viii recombinantes. | |
| BR112016007816A2 (pt) | composições peptídicas inovadoras |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |